Suzhou Ribo moves to take full control of Swedish siRNA unit Ribocure
What's the deal? Suzhou Ribo Life Science (06938.HK) plans to acquire the remaining 49.71% of its Swedish subsidiary, Ribocure Pharmaceuticals, lifting its stake from 50.29% to 100%. The company signed a share-swap agreement with Ribocure's minority shareholders on October 16, 2026, and announced the deal on October 19. The transaction value was undisclosed.
How is it structured? Ribo will issue about 14,087,085 new H shares as consideration, with minority holders receiving 15 Ribo shares for each Ribocure share. The new stock equals 7.63% of the company's enlarged share capital. The deal requires no cash, but it dilutes existing shareholders.
What each side does: Ribo develops oligonucleotide, or siRNA, therapeutics and is listed in Hong Kong. Ribocure, founded in Gothenburg in February 2022 by Ribo and Dr. Li-Ming Gan's team, runs the group's global clinical and business development in cardiovascular, renal, and metabolic diseases.
Why now? Ribocure has become central to Ribo's overseas push. In February, Ribo licensed six MASH siRNA programmes to Madrigal for $60 million upfront and up to $4.4 billion in potential milestones; in October it filed a Phase 1 trial application in the EU for candidate RBD3133.
What's the endgame? Full ownership means all of Ribocure's operating earnings and pipeline value flow to Ribo's listed shareholders. "Structured purely as a share swap, the transaction requires no cash outlay from the Company," Ribo said, adding that it can streamline cross-entity decision-making.
What could go wrong? Many of the programmes behind the value case remain early-stage, so milestone payments are not guaranteed revenue. The deal still needs approval from independent shareholders and regulators.
The signal: The move folds a key European research and partnership vehicle fully inside a Chinese biotech, consolidating the economics of a global siRNA platform without spending cash — a sign of how cross-border drug developers are tightening control over their most strategic assets.
Read more: sohu.com
Image credit: Generated with Gemini
